TB-500 research: thymosin beta-4 in plain language

Research context (RUO): TB-500 is a synthetic fragment of the body's own protein thymosin beta-4, studied in animal models for tissue repair. It is supplied solely for in-vitro laboratory research and is not intended for human or animal use.

TB-500 research: thymosin beta-4 in plain language

Together with BPC-157, TB-500 is the best-known repair peptide in the research field. Where BPC-157 mainly revolves around blood-vessel formation, a different process is central to TB-500: moving cells to the place where repair is needed. In this guide we explain in plain language what TB-500 is, how researchers think it works, and what the evidence does and does not show — always within the boundaries of the laboratory.

What is TB-500?

TB-500 is a synthetic, short version of an endogenous protein called thymosin beta-4 (TΒ4). That protein occurs in virtually every cell and plays a role in regulating actin — the “skeleton” and locomotor apparatus inside cells. TB-500 contains the active part of thymosin beta-4 that is thought to be responsible for directing cell movement. Because it is small and stable, researchers use it as a convenient model molecule.

How does TB-500 work? — the mechanism in plain language

Recovery is largely a logistics problem: the right cells have to reach the right place. TB-500 acts precisely there. Because it binds to actin, in research it is associated with cell migration — the ability of repair cells to migrate towards damaged tissue. Studies also link it to blood-vessel formation (angiogenesis) via VEGF and HIF signalling, to dampening inflammation and to “refurbishing” the connective-tissue matrix around cells. In short: where BPC-157 mainly lays the supply lines (blood vessels), TB-500 mainly helps the construction workers (cells) get into position — one reason they are often studied together in research.

What is TB-500 studied for?

• Tissue repair: in animal models of muscle, tendon and cardiac damage, TB-500 (or thymosin beta-4) was associated with faster recovery.
• Blood-vessel formation: studies link it to the formation of new blood vessels in healing tissue.
• Inflammation regulation: researchers are studying whether it tempers excessive inflammatory responses.
• Heart: thymosin beta-4 has been extensively studied in models of cardiac damage and cell survival.

What the evidence does and does not say

As with BPC-157, honesty matters here. An extensive scoping review (2026) that mapped dozens of studies places the mechanism around cell migration, angiogenesis, inflammation modulation and matrix repair — but at the same time concludes that there no intervention studies in humans for tendon, ligament or muscle repair. The evidence is therefore largely preclinical. The authors warn explicitly: “biological plausibility” is not the same as clinical evidence. That makes TB-500 an interesting but not yet fully developed research subject.

TB-500 in the lab: handling & reconstitution

TB-500 is supplied as a freeze-dried powder that is reconstituted before use, usually with bacteriostatic water. Cool storage and limiting freeze-thaw cycles are part of good laboratory practice. See reconstitute peptides and which liquid you choose.

Thymosin beta-4 versus TB-500: where is the difference?

In practice the two terms get mixed up. Thymosin beta-4 is the full endogenous protein of 43 amino acids. TB-500 is a synthetic fragment of seven amino acids matching the active core motif. So when you read studies, you have to check carefully which of the two substances was actually investigated.

What the clinical research with thymosin beta-4 showed

The most advanced clinical work is in ophthalmology. RegeneRx studied thymosin beta-4 as eye drops (RGN-259) in phase 3 trials for dry eye and neurotrophic keratitis. Results were mixed: individual endpoints such as complete corneal healing were met, others were not. That picture is typical for this substance, because laboratory findings on cell migration and new vessel formation do not automatically translate into clinical endpoints.

Half-life and why the dosing interval in protocols is so wide

Thymosin beta-4 has a short plasma half-life, in animal studies in the region of about two hours. Even so, many research protocols work with intervals of several days. The reason is that the measured effects on gene expression and cell migration persist longer than the substance itself is detectable. Plasma concentration is therefore a poor indicator of how long the biological effect lasts.

Status in the doping rules

TB-500 is on the WADA prohibited list under S2, peptide hormones and growth factors, and is banned at all times. That applies regardless of whether the full protein or the fragment is used. There is more on this in our overview of peptides and doping rules.

Quality & purity

Every relevant batch is independently HPLC-tested by an external laboratory; the CoA is publicly verifiable per batch. This makes it verifiable what is actually in the vial — see also why we rejected a batch.

Frequently asked questions about TB-500

What exactly is TB-500?
A synthetic fragment of the body's own protein thymosin beta-4. It contains the active part that drives cell movement (via actin) and is studied in research on tissue repair.

Is TB-500 the same as thymosin beta-4?
Not quite. TB-500 is a short, synthetic version that mimics the active part of the full Tβ4 protein. In studies both terms are often used interchangeably.

What is the difference from BPC-157?
BPC-157 is mainly associated with blood-vessel formation and tendons; TB-500 mainly with cell migration. Read the comparison BPC-157 vs TB-500.

Is TB-500 proven in humans?
No. The evidence is preclinical; there are no intervention studies in humans for tissue repair. Peplife makes no usage or dosing claims.

May I use TB-500?
No. TB-500 is intended solely for in-vitro laboratory research (RUO), not for human or animal use.

Read more & research at Peplife

• Research TB-500 at Peplife
• BPC-157 research · BPC-157 vs TB-500
• Wolverine blend (BPC-157 + TB-500)
• Muscle-recovery peptides: the overview
• View all recovery peptides
• Hair growth peptides: which pathways are being researched

Sources: Scoping review thymosin beta-4 / TB-500, Applied Sciences (2026) · Thymosin beta-4, cell migration & repair (PubMed)

Research Use Only. All products are supplied exclusively for in vitro laboratory research. Not intended for diagnostic or therapeutic use in humans or animals, and not approved by the EMA or FDA.